Transaction #3716 · Form 4 · 0000874716-25-000166
IDEXX LABORATORIES INC /DE · Stock award · Common Stock
IDEXX LABORATORIES INC /DE · Transacted October 30, 2025 · Filed November 3, 2025
What does this filing report?
An SEC Form 4 filing for IDEXX LABORATORIES INC /DE records a stock award involving Common Stock on October 30, 2025. The reported quantity was 39. The filing date is November 3, 2025. This is one transaction record; amounts are not allocated among any joint reporting owners.
The acquisition category describes how securities were received. It does not by itself establish a cash purchase of common stock. Read the transaction code definitionsand the original filing before interpreting the amounts.
Transaction details
- Company
- IDEXX LABORATORIES INC /DE
- Company CIK
- 0000874716
- Security type
- Non-derivative
- Acquisition type
- Stock award · Code A
- Quantity acquired
- 39
- Reported price
- 628.54
- Reference value
- 24,513.06
- Currency
- Currency not specified
- Ownership
- Direct
- Holdings after transaction
- 39
- Ownership description
- Not reported
- SEC acceptance time
- Nov 3, 2025, 5:00 PM EST
- 10b5-1 indication
- Not indicated
Reference value is reported quantity × reported price. It is not a confirmed cash payment or an estimate of a derivative's economic value. A missing currency is not assumed to be USD.
Reporting owners
- HOOLEY JOSEPH L ↗
Director
CIK 0001123847
These are the reporting owners named in the filing. Quantities and amounts are not allocated among co-reporters. Roles reflect this filing, not a current profile.
Company listings
The linked listing is identified separately from other current company listings.
Filing footnotes & remarks
- F1
- Represents deferred stock units acquired pursuant to the IDEXX Laboratories, Inc. Director Deferred Compensation Plan (the 'Plan') in accordance with Rule 16b-3. The number of deferred stock units, rounded up or down to the nearest whole unit, is determined by dividing the amount of cash compensation deferred pursuant to the Plan ($24,375.00) by the closing price of IDEXX Laboratories, Inc. common stock on the date of the deferral, or if no such price is reported for that date, the closing price for the next preceding date for which such price was reported. Each deferred stock unit represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. The deferred stock units vest immediately upon grant and are payable only as common stock as soon as practicable following the Director's resignation from the Board of Directors or on such other nondiscretionary and objectively determinable date(s) selected in accordance with the terms of the Plan.
Footnotes are reproduced as plain text from the current source filing. For the full context, read the original SEC filing.
This record was updated Eastern Time. This is the stored record update time, not the transaction date. Report a correction.